IR-arkiv | Affibody Medical AB

Affibody Medical Investor Relations

Categories:

Navigation:

Regulatory

October 7, 2025

First Patient Dosed in Phase 1 Clinical Study with Affibody’s Radiotherapeutic ABY-271 in HER2-positive Metastatic Breast Cancer

Solna, Sweden, October 7, 2025. Affibody AB (“Affibody”) today announced that the first patient has been dosed in a Phase 1 clinical study with the company’s radiotherapeutic candidate ABY-271...

Regulatory

September 30, 2025

Affibody Announces Broad Scientific Progress at EANM 2025

Solna, Sweden, September 30, 2025. Affibody AB (“Affibody”) today announced it will have substantial scientific presence at the 2025 Congress of the European Association of Nuclear Medicine (EANM), taking...

Regulatory

September 19, 2025

Positive 16-week Phase 3 Data of Izokibep in Hidradenitis Suppurativa Presented at EADV 2025

Solna, Sweden, September 19, 2025. Affibody AB (“Affibody”) today announced positive 16-week data from a global Phase 3 study of izokibep in hidradenitis suppurativa (HS) that was presented at...

Regulatory

September 11, 2025

Positive 16-week Phase 3 Data of Izokibep in Hidradenitis Suppurativa to be Presented at EADV 2025 Late Breaking Session

Solna, Sweden, September 11, 2025. Affibody AB (“Affibody”) today announced that positive 16-week data from a global Phase 3 study of izokibep in hidradenitis suppurativa (HS) will be presented...

Regulatory

June 13, 2025

Affibody’s licensee Rallybio Announces Initiation of Dosing with RLYB116 in Phase 1 Confirmatory PK/PD Study

Solna, Sweden, June 13, 2025. Affibody’s licensee Rallybio Corporation (Rallybio) has announced the initiation of dosing in a Phase 1 confirmatory pharmacokinetic/pharmacodynamic (PK/PD) study evaluating RLYB116, an innovative, once-weekly,...

Regulatory

May 27, 2025

Report from Annual General Meeting in Affibody Medical AB (publ)

Stockholm, Sweden, May 27, 2025 – Affibody Medical AB (publ) today held its Annual General Meeting. The following resolutions were adopted. Adoption of the income statement and the balance...

Regulatory

April 25, 2025

NOTICE OF ANNUAL GENERAL MEETING IN AFFIBODY MEDICAL AB (PUBL)

The shareholders of Affibody Medical AB (publ), corporate identity number 556714-5601 (the “Company” or “Affibody”) are hereby invited to attend the annual general meeting of the shareholders on Tuesday...

Regulatory

December 10, 2024

Affibody’s Licensee ACELYRIN Announces Top-line Results for Izokibep in Uveitis

Stockholm, Sweden, December 10, 2024. Affibody’s licensee ACELYRIN, INC. today announced that the Phase 2b/3 trial of izokibep in non-infectious, non-anterior uveitis did not meet the primary endpoint. Izokibep...

Regulatory

August 13, 2024

Positive Phase 3 Results in Hidradenitis Suppurativa Further Strengthen Competitive Profile of Izokibep

• Phase 3 trial of izokibep in patients with hidradenitis suppurativa met primary endpoint of HiSCR75 at week 12, as well as the key secondary endpoints of HiSCR90 and...